O V E R V I E W
Cellmig Biolabs is a clinical pharmaceutical company committed to developing novel medicines for the diagnosis and treatment of tumor metastasis and cancers. Cellmig has developed breakthrough biotechnologies to detect cancer cell dissemination at various stages including the early stage.
Cellmig has a portfolio of novel product candidates targeting membrane enclsoed tubular pathways of cancer cell metastasis. Cellmig's lead program, Cellmig-216, is in approaching clinical development for the detection of tumor metastasis in patient tissues. Cellmig is developing other kits, including Cellmig-139, for the specific and accurate diagnosis of tumor metastasis with both in vitro and in vivo detections.
Cellmig is developing its product candidates, including Cellmig-328, targeting inhibition of tumor cell metastasis via membrane enclsoed tubular pathways in various cancers at diverse stages, aimed for the pharmatherapy of tumor metastasis and cancer.
Investor Inquiries
Media Inquiries
Cellmig Biolabs Inc.
Address: 675 West Kendall Street
Cambridge, MA 02142
